In one aspect, the invention relates to compounds having the formula: ##STR00001##
where X, R.sup.a, R.sup.b, R.sup.2, and R.sup.7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.

The present disclosure relates to methods for preventing progressive heart failure in subjects with persistent left ventricular (LV) dysfunction. Such methods may also be used for treating or preventing progressive heart failure in subjects with a proximal left anterior descending (LAD) lesion and persistent left ventricular dysfunction.

Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.

Disclosed are compounds of Formula (I)

##STR00001##

or a salt thereof,
wherein R.sup.1 is:

##STR00002##

each W is independently NR.sub.1b or O; Z is a bond or CHR.sup.1d; and R.sup.1, R.sup.2, R.sup.d, R.sup.3a, R.sup.3b, L.sup.1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

Provided are compounds of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R.sup.1, R.sup.2, R.sup.3, G.sub.1, G.sub.2, and G.sub.3 are as defined herein.

Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Provided are compounds of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R.sup.1, R.sup.2, R.sup.3, G.sub.1, G.sub.2, and G.sub.3 are as defined herein.

Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of prevention and/or treatment of cardiovascular disease and/or conditions. In one embodiment of the invention, said compounds and compositions of the invention maintain or improve cardiovascular tissue and cellular function. In another embodiment of the invention, said compounds and compositions of the invention enhance cardiovascular recovery after injury or surgery.

The present invention falls within the technical field of medicine, and in particular relates to a crystal form of a phosphodiesterase inhibitor as shown in formula (I), a preparation method therefor and the use thereof.

##STR00001##